Medidata names new CEO and claims 30,000 trial milestone
Top table changes will help it cater for growing digitization of biopharmaceutical research and development, says Medidata.
The US clinical trial technology firm announced changes to its leadership team last week, naming Pascal Daloz, an executive at parent firm Dassault Systèmes, as its CEO.
Daloz – who joined Dassault in 2001 – helped drive the firm’s $5.8 billion takeover of Medidata in 2019. He replaces co-CEOs Rama Kondru and Sastry Chilukuri, who took on leadership of Medidata in late September 2021.
In a press statement he said “customers are asking to do more with Medidata, and we are evolving to meet their digital transformation needs.
“We are extremely committed to this industry and will continue investing to achieve the vision that includes prevention to precision medicine and discovery to distribution, in order to be at the center of every patient journey.”
In addition, Michael Pray – previously Medidata’s chief commercial officer - was appointed as chief operating officer.
According to a company statement the “new leadership structure designed to fuel its mission of creating end-to-end solutions that power smarter treatments and healthier people.
“The strategic evolution is an opportunity to further long-term goals and growth to enhance customers’ ability to unlock greater value across the Dassault Systèmes portfolio, ultimately taking drug development to new heights.”
Business details
Medidata followed the C-suite changes with the announcement it has now been involved in more than 30,000 clinical trials worldwide.
The firm claimed its tech is used in nearly 40% of company-initiated trial starts globally and that around 70% of new drugs approved by the US Food and Drug Administration (FDA) in 2022 were developed with its software.
This is in keeping with what parent firm Dassault Systèmes said in a recent report when it cited Medidata as a key factor in the 12% increase – to €302.5 million – seen in life sciences software revenue in the fourth quarter.
“Medidata continued to deliver strong performance, driven by broad-based growth across product lines and end-markets.”
Unsplash/katetrysh